2017版体细胞变异分级指南全球采用率上升,实践差异与机构类型相关
该研究通过问卷调查评估2017年AMP/ASCO/CAP体细胞变异分级指南在参加CAP能力验证的实验室中的采用与实施情况。结果显示,NGSST和NGSHM参与者中分别有64.4%和66.4%使用分级系统,其中84.9%和73.6%采用2017版指南,采用者满意度高且认为重复性较好。部分实验室对指南进行了修改,非学术实验室更倾向于增加亚分级。
要点
- 全球超过50%的CAP实验室已实施2017版体细胞变异分级指南。
- 使用指南的实验室满意度高,对分级重复性的印象评分较高。
- 未来指南修订应关注疾病监测和胚系变异,亚分级需求因机构类型而异。
核心结论
- 2017版指南已被超过50.0%的CAP实验室实施,多数使用者满意,但适度的指南修改可能进一步提升质量、重复性和临床实用性。
研究设计与样本
- 向参与实体瘤(NGSST)和血液恶性肿瘤(NGSHM)NGS CAP能力验证的实验室发放问卷调查。
主要发现
- 全球64.4%(152/236)的NGSST和66.4%(87/131)的NGSHM参与者使用分级系统,其中2017版指南使用率分别为84.9%(129/152)和73.6%(64/87)。
- 24.4%(30/123)的NGSST和21.7%(13/60)的NGSHM实验室对2017版指南进行了修改。
- 实施2017版指南的实验室满意度高(NGSST 74.2% [89/120],NGSHM 69.5% [41/59]),重复性印象评分均值分别为3.9和3.6(5分制)。
- 未使用者中,35.2%(38/108)的NGSST和39.4%(26/66)的NGSHM实验室计划实施。
- 对未来指南修订,受访者支持纳入疾病监测变异(NGSST 63.9% [78/122],NGSHM 80.0% [48/60])和胚系变异(NGSST 55.3% [63/114],NGSHM 75.0% [45/60]);学术实验室相比非学术实验室更不赞成增加亚分级(NGSST P < .001,NGSHM P = .02)。
临床怎么用
- 病理科智能体可参考2017版指南进行体细胞变异分级,但需注意实验室间存在修改和实践差异。
- 在报告体细胞变异时,应考虑纳入疾病监测和胚系变异信息,并关注机构类型对分级细化的不同需求。
局限性
- 研究基于问卷调查,可能存在回复偏倚;未评估指南实施对临床结局的实际影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: The 2017 Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists (CAP) tier classification guideline provides a framework to standardize interpretation and reporting of somatic variants. OBJECTIVE.—: To evaluate the adoption and performance of the 2017 guideline among laboratories performing somatic next-generation sequencing (NGS). DESIGN.—: A survey was distributed to laboratories participating in NGS CAP proficiency testing for solid tumors (NGSST) and hematologic malignancies (NGSHM). RESULTS.—: Worldwide, 64.4% (152 of 236) of NGSST and 66.4% (87 of 131) of NGSHM participants used tier classification systems, of which the 2017 guideline was used by 84.9% (129 of 152) of NGSST and 73.6% (64 of 87) of NGSHM participants. The 2017 guideline was modified by 24.4% (30 of 123) of NGSST and 21.7% (13 of 60) of NGSHM laboratories. Laboratories implementing the 2017 guideline were satisfied or very satisfied (74.2% [89 of 120] NGSST and 69.5% [41 of 59] NGSHM), and the impression of tier classification reproducibility was high (mean of 3.9 [NGSST] and 3.6 [NGSHM] on a 5-point scale). Of nonusers, 35.2% (38 of 108) of NGSST and 39.4% (26 of 66) of NGSHM laboratories were planning implementation. For future guideline revisions, respondents favored including variants to monitor disease (63.9% [78 of 122] NGSST, 80.0% [48 of 60] NGSHM) and germline variants (55.3% [63 of 114] NGSST, 75.0% [45 of 60] NGSHM). Additional subtiers were not favored by academic laboratories compared to nonacademic laboratories (P < .001 NGSST and P = .02 NGSHM). CONCLUSIONS.—: The 2017 guideline has been implemented by more than 50.0% of CAP laboratories. While most laboratories using the 2017 guideline report satisfaction, thoughtful guideline modifications may further enhance the quality, reproducibility, and clinical utility of the 2017 guideline for tiered somatic variant classification.
引用
- Bruehl FK, Kim AS, Li MM, et al. Tiered Somatic Variant Classification Adoption Has Increased Worldwide With Some Practice Differences Based on Location and Institutional Setting. Arch Pathol Lab Med. 2022. PMID: 34979564. doi:10.5858/arpa.2021-0179-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。